Table of Contents
PPT Slide
Acknowledgements
Cervical Cancer Global Perspective
Cervical Cancer U.S.A. Perspective
Precursor Lesions of Cervical Carcinoma
PPT Slide
Cervical Lesions: “Pyramid” of Findings (U.S.)*
Natural History of CIN
Natural History of CIN
Natural History of Cervical Dysplasiaa
HPV Vaccine Composition
Squamous Cell Carcinoma* - HPV 16 Most Common Type
Adenocarcinoma (Cervix) - HPV 18 - Most Common Type
Incidence of Squamous Cell Carcinoma (SCC) vs. Adenocarcinoma (ADC) of the Cervix
Risk of CIN 2 or 3: Relation to HPV Type 16 and 18
Risk of CIN 2 or 3: Relation to HPV Type 16
PPT Slide
“Theoretical” Endpoints - HPV Preventive Vaccines
Possible Endpoints – HPV Vaccines
Possible Endpoints – HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Possible Endpoints - HPV Vaccines
Efficacy Trial Analysis
Accelerated Approval (AA)
Accelerated Approval (AA)
Accelerated Approval (AA)
FDA Questions
FDA Questions (continued)
|